HK1064621A1 - Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof - Google Patents

Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof

Info

Publication number
HK1064621A1
HK1064621A1 HK04107696.8A HK04107696A HK1064621A1 HK 1064621 A1 HK1064621 A1 HK 1064621A1 HK 04107696 A HK04107696 A HK 04107696A HK 1064621 A1 HK1064621 A1 HK 1064621A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
methods
bind
cancer
associated antigen
Prior art date
Application number
HK04107696.8A
Inventor
Jennie Powell Mather
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Publication of HK1064621A1 publication Critical patent/HK1064621A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas. Methods of diagnosing and treating various cancers by using antibodies such as mPA7 directed against this antigen are also disclosed.
HK04107696.8A 2001-10-16 2004-10-07 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof HK1064621A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32964401P 2001-10-16 2001-10-16
PCT/US2002/033116 WO2003032814A2 (en) 2001-10-16 2002-10-16 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1064621A1 true HK1064621A1 (en) 2005-02-04

Family

ID=23286361

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107696.8A HK1064621A1 (en) 2001-10-16 2004-10-07 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof

Country Status (7)

Country Link
US (2) US7148038B2 (en)
EP (1) EP1441766B1 (en)
JP (1) JP4347694B2 (en)
AT (1) ATE524196T1 (en)
CA (1) CA2463927A1 (en)
HK (1) HK1064621A1 (en)
WO (1) WO2003032814A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106179A (en) * 2014-09-12 2022-03-01 加利福尼亚大学董事会 Macrocytic human anti-CD 46 antibodies and targeted cancer therapies

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441766B1 (en) 2001-10-16 2011-09-14 MacroGenics West, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
KR20050038005A (en) * 2002-07-18 2005-04-25 헬릭스 바이오파마 코포레이션 Use of urease for inhibiting cancer cell growth
US20050226873A1 (en) * 2003-09-30 2005-10-13 Del Priore Lucian V Medical devices and methods for modulating cell adhesion
PE20050925A1 (en) 2003-11-10 2005-11-29 Schering Corp RECOMBINANT ANTI-INTERLEUQUIN HUMANIZED ANTIBODY 10
WO2005093063A1 (en) * 2004-03-29 2005-10-06 Medical & Biological Laboratories Co., Ltd. Kit for solid cancer diagnosis and medicine for solid cancer therapy
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8309354B2 (en) * 2007-01-22 2012-11-13 Macrogenics West, Inc. Human cancer stem cells
EP2192922A4 (en) 2007-09-17 2010-09-29 Univ California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
KR101940059B1 (en) 2008-12-19 2019-01-18 마크로제닉스, 인크. Covalent diabodies and uses thereof
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
ES2667100T3 (en) 2010-08-02 2018-05-09 Macrogenics, Inc. Covalent Diabodies and Their Uses
EP2689787A1 (en) * 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
AU2011295715B9 (en) * 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
US8642951B2 (en) 2011-05-04 2014-02-04 Agilent Technologies, Inc. Device, system, and method for reflecting ions
AU2012259162C1 (en) 2011-05-21 2020-05-21 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
US9567402B2 (en) * 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
WO2015007887A1 (en) * 2013-07-19 2015-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a ligand of hvem and an immunotoxin for use in therapy
AU2014360318B2 (en) 2013-12-05 2019-10-31 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)
NZ726514A (en) 2014-05-29 2019-01-25 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP3250142A4 (en) 2015-01-30 2018-11-21 Rfemb Holdings LLC Radio-frequency electrical membrane breakdown for the treatment of tissues
HUE056201T2 (en) 2015-07-30 2022-02-28 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
TWI758267B (en) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CN109069624A (en) 2016-01-15 2018-12-21 瑞美控股有限责任公司 The immunization therapy of cancer
CN105462935B (en) * 2016-01-20 2017-08-04 潘世扬 Ovarian cancer resistance monoclonal antibody and its application
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
MX2020006155A (en) 2017-12-12 2020-08-13 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease.
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
MX2023001625A (en) 2020-08-07 2023-05-16 Fortis Therapeutics Inc Immunoconjugates targeting cd46 and methods of use thereof.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5496550A (en) 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
DE10299017I2 (en) 1987-06-22 2005-05-25 Medeva Holdings Bv Hepatitis B surface antigen-containing peptide.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5514787A (en) 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
EP0483247A4 (en) 1989-07-21 1992-12-09 Washington University Recombinantly produced human membrane cofactor protein (mcp)
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5846715A (en) 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP3919830B2 (en) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 Anti-feline herpesvirus-1 recombinant antibody and gene fragment encoding the antibody
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5773247A (en) 1993-01-14 1998-06-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-HIV antibody and process for preparing the same
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5665570A (en) 1994-02-10 1997-09-09 Takeda Chemical Industries, Ltd. Antibody-encoding recombinant DNA and its use
AU2077197A (en) 1996-03-18 1997-10-10 Novo Nordisk Biotech, Inc. Polypeptides having phytase activity and nucleic acids encoding same
CN1209837A (en) 1996-10-18 1999-03-03 财团法人阪大微生物病研会 Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus and process for producing same
WO1998034635A1 (en) * 1997-02-07 1998-08-13 The Wistar Institute Methods and compositions for the inhibition of interleukin-12 production
CN1044092C (en) * 1997-02-26 1999-07-14 上海医科大学 Antigen-antibody-recombination DNA composite type vaccin
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU2001261259A1 (en) 2000-05-12 2001-11-26 Anil K. Kaul Diagnostic method for screening complement regulatory protein levels
US20030129677A1 (en) * 2000-05-12 2003-07-10 Martens Mark G. Diagnostic method for screening complement regulatory protein levels
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
EP1184458A1 (en) * 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1441766B1 (en) * 2001-10-16 2011-09-14 MacroGenics West, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
CN1655671A (en) * 2002-05-30 2005-08-17 雷文生物技术公司 Animal model for toxicology and dose prediction
EP1560597A4 (en) * 2002-10-29 2007-06-27 Pharmacia Corp Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
EP1819731A4 (en) * 2004-12-08 2013-02-13 Immunomedics Inc Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106179A (en) * 2014-09-12 2022-03-01 加利福尼亚大学董事会 Macrocytic human anti-CD 46 antibodies and targeted cancer therapies

Also Published As

Publication number Publication date
EP1441766B1 (en) 2011-09-14
US20030108966A1 (en) 2003-06-12
JP4347694B2 (en) 2009-10-21
US7148038B2 (en) 2006-12-12
WO2003032814A3 (en) 2003-09-12
WO2003032814A2 (en) 2003-04-24
JP2005511525A (en) 2005-04-28
EP1441766A4 (en) 2006-03-08
CA2463927A1 (en) 2003-04-24
US20070128202A1 (en) 2007-06-07
EP1441766A2 (en) 2004-08-04
ATE524196T1 (en) 2011-09-15
US7744878B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
HK1064621A1 (en) Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
HK1108163A1 (en) Antibodies that bind to epha2 and methods of use thereof
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
RS80704A (en) ANTI- av?6.ANTIBODIES
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
NZ596317A (en) Antibodies directed to her-3 and uses thereof
HK1074634A1 (en) Internalizing antibodies specific for the raag10 cell surface target
TR200202799T3 (en) Humanized antibodies that sequence the AB peptide
EP1363920A4 (en) Modified psma ligands and uses related thereto
DE602006013029D1 (en) ANTI-EGFR ANTIBODY
MXPA06010673A (en) Reducing the risk of human and anti-human antibodies through v gene manipulation.
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
TW200510459A (en) RG1 antibodies and uses thereof
MX347883B (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof.
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
MX2022001049A (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses.
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2006076584A3 (en) Kid31 and antibodies that bind thereto
WO2003093443A3 (en) Alcam and alcam modulators
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
EP1546205A4 (en) Methods for regulating cancer
WO2003064593A3 (en) Antigen panels and methods of using the same
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151016